Expected Moves

Fiscal third-quarter results with updated modeling on Japan's National Health Insurance (NHI) biennial drug price revisions.

Anticipated Ministry of Health, Labour and Welfare (MHLW) approvals for new specialty injectables and biosimilar portfolio expansions.

Full-year earnings announcement accompanied by forward fiscal year guidance and potential dividend/buyback declarations.